Cancer treatments have evolved from indiscriminate cytotoxic agents to selective genome and immune targeted drugs that have transformed the outcomes of some malignancies. Tumor complexity and heterogeneity suggest that the precision medicine paradigm of cancer therapy requires treatment to be personalized to the individual patient. To date, precision oncology trials have been based on molecular matching with predetermined monotherapies. Several of these trials have been hindered by very low matching rates, often in the 5 10% range, and low response rates. Low matching rates may be due to the use of limited gene panels, restrictive molecular matching algorithms, lack of drug availability, or the deterioration and death of end stage patients before therapy can be implemented, the investigators wrote. We hypothesized that personalized treatment with combination therapies would improve outcomes in patients with refractory malignancies. As a first test of this concept, we implemented a cross institutional prospective study that used tumor DNA sequencing and timely recommendations for individualized treatment with combination therapies. We found that administration of customized multidrug regimens was feasible, with 49% of consented patients receiving personalized treatment. Targeting of a larger fraction of identified molecular alterations, yielding a higher matching score , was correlated with significantly improved disease control rates, as well as longer progression free and overall survival rates, compared to targeting of fewer somatic alterations.
Some 45 percent of youngsters with cancer are left undiagnosed and untreated, according to an innovative study of the disease s global footprint among under 15s, published Wednesday. Worldwide, there are some 400,000 new cases of childhood cancer annually, however barely 0.5 are logged in national health registries, researchers reported in The Lancet Oncology, a medical journal. The patients can virtually actually die, although cancer won 't be listed on a death certificate, noted Eva Steliarova Foucher, a scientist at the UN backed International Agency for Research on Cancer, commenting on the study. Sixty percent of countries don 't even have cancer registries, and of those that do may only cover a fraction of the population.
Some 45 percent of children with cancer are left undiagnosed and untreated, according to an innovative study of the disease 's global footprint among under 15s, published Wednesday. Worldwide, there are some 400,000 news cases of childhood cancer each year, but barely half are logged in national health registries, researchers reported in The Lancet Oncology, a medical journal.
Dr Shirish Alurkar, Director of Clinical Services at Apollo in the city said cancer in India is being detected at an early age. "The best strategy is to ensure early detection and this can be done by screening and prevention. This is also the reason why we are focusing on preventive oncology, " said Dr Alurkar.He said they are now also targeting relatives of cancer patients to encourage them to go for screening and preventive check ups.
Advances in immunotherapy are improving outcomes for patients with various cancers. In addition, the immunogenicity of breast cancer is leading to increasingly optimistic views on the use of immunotherapy to treat various subtypes of breast cancer, in particular HER2 overexpressing subtype.In this review, researchers from Jordan and the United States describe the immune microenvironment of HER2 positive breast cancer. Current and emerging immunotherapies and their potential in the treatment of breast cancer, including immune checkpoint inhibitors, therapeutic vaccines, and adoptive T cell immunotherapy, are explored.
A 240 million year old turtle died with a type of bone cancer that still haunts the living, National Geographic reports. The ancient turtle s fossilized hind leg included a malignancy the researchers identified as a type of bone cancer that strikes about 800 Americans each year. Cancer is extraordinarily rare in the fossil record because it typically affects soft tissues that aren t preserved. Paleontologists unearthed this relative of modern turtles (Pappochelys rosinae) in 2008 near Stuttgart, Germany. Researchers pegged the fossilized cancer as periosteal osteosarcoma, noting it was almost identical to osteosarcomas afflicting humans today, they reported earlier this week in JAMA Oncology. This 240 million year old cancer is the earliest case ever recorded in an amniote the group including reptiles, birds, and mammals suggesting cancers of today and the genes underlying them have roots deep in evolutionary time.
In a landmark development, Lupin Limited on Monday announced a partnership with US headquartered global biopharmaceutical player AbbVie Inc for developing novel oncology drug to treat haematological cancer.Following the partnership, AbbVie gains exclusive global rights to develop and commercialise Lupin s MALT1 (Mucosa Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitors.
The reason it;s so deadly is that these cancer cells lack the docking points for three proteins mdash; the hormones estrogen and progesterone, and human epidermal growth factor receptor 2 (called HER2) mdash; that effective drugs can latch on to in order to destroy tumors. Women diagnosed with triple negative breast cancer, who make up 15% to 20% of breast cancer patients, often try chemotherapy after chemotherapy, working through each drug until their cancer starts growing again, at which point they move on to the next drug.But in a presentation at the European Society for Medial Oncology in Munich, scientists reported that combining chemotherapy with an immunotherapy drug helped lower risk of their disease progressing, and of death, by 20% compared to women treated with chemotherapy alone. The research was conducted in 900 women with metastatic triple negative breast cancer who were randomly assigned to receive the combination therapy or just chemotherapy.
Campbell Newman Asset Management Inc decreased its stake in International Business Machine (IBM) by 78.08% based on its latest 2018Q1 regulatory filing with the SEC. Campbell Newman Asset Management Inc sold 52,338 shares as the company 's stock declined 9.42% with the market. The institutional investor held 14,691 shares of the computer manufacturing company at the end of 2018Q1, valued at $2.25 million, down from 67,029 at the end of the previous reported quarter. Campbell Newman Asset Management Inc who had been investing in International Business Machine for a number of months, seems to be less bullish one the $132.96 billion market cap company. The stock decreased 1.27% or $1.87 during the last trading session, reaching $144.84. About 1.90M shares traded. International Business Machines Corporation (NYSE:IBM) has declined 6.24% since July 27, 2017 and is downtrending. It has underperformed by 18.81% the S #038;P500. Some Historical IBM News: 06 03 2018 - Robin Systems announces extension of Hybrid Cloud support to Microsoft Azure as well as for SAP HANA, MS SQL, IBM DB2 #038; Packaged Enterprise Applications; 26 03 2018 - EUROPEAN COMMISSION APPROVES JOINT VENTURE BETWEEN IBM IBM.N AND MAERSK MAERSKB.CO; 27 03 2018 - CORRECT: IBM EARNINGS WERE NOT RELEASED; 24 05 2018 - SBERBANK, IBM SIGN AGREEMENT ON WATSON FOR ONCOLOGY; 08 05 2018 - CryptoCoin: ANZ #038; IBM Develop Blockchain Insurance Solution; 15 05 2018 - BERKSHIRE HATHAWAY DISSOLVES SHARE STAKE IN GRAHAM HOLDINGS CO SEC FILING; 30 05 2018 - Graph Blockchain Receives First Payment From IBM; 06 03 2018 - PacketFabric Offers Connectivity to IBM Cloud; 19 03 2018 - Canada Launches C$400m 5G Project With Five Firms Including IBM; 17 04 2018 - IBM 1Q EPS $1.81
Marco Investment Management Llc increased its stake in International Business Machs (IBM) by 52.43% based on its latest 2018Q1 regulatory filing with the SEC. Marco Investment Management Llc bought 7,626 shares as the company 's stock declined 9.42% with the market. The institutional investor held 22,170 shares of the computer manufacturing company at the end of 2018Q1, valued at $3.40M, up from 14,544 at the end of the previous reported quarter. Marco Investment Management Llc who had been investing in International Business Machs for a number of months, seems to be bullish on the $133.23B market cap company. The stock decreased 1.07% or $1.57 during the last trading session, reaching $145.14. About 2.35 million shares traded. International Business Machines Corporation (NYSE:IBM) has declined 6.24% since July 27, 2017 and is downtrending. It has underperformed by 18.81% the S #038;P500. Some Historical IBM News: 08 03 2018 - IBM CEO GINNI ROMETTY SPEAKS ON INVESTOR WEBCAST; 09 03 2018 - IBM Closes Above 50 Day Moving Average: Technicals; 22 05 2018 - Apollo Hospitals Adopts IBM Watson for Oncology and IBM Watson for Genomics to Help Physicians Make Data Driven Cancer Care Decisions; 27 04 2018 - Amazon Web Services: New on AWS DB Blog: AWS DMS and AWS SCT now support IBM Db2 as a source; 17 04 2018 - IBM - TOTAL CLOUD REVENUE OVER THE LAST 12 MONTHS WAS $17.7 BILLION, UP 22 PERCENT (UP 20 PERCENT ADJUSTING FOR CURRENCY); 15 05 2018 - BERKSHIRE 13F NO LONGER SHOWS STAKE IN IBM AS OF 1Q; 10 05 2018 - IBM Announces Collaboration with North Carolina State University to Accelerate Quantum Computing; 03 05 2018 - The Doss Firm, LLC and O 'Dell #038; O 'Neal, Inc.: Investment Fraud Claims Filed Against CUNA Brokerage Services, Inc., IBM Southeas; 22 03 2018 - MOVES Ernst #038; Young hires three executive directors, principal; 16 05 2018 - TTA Receives Outstanding Work Review from Long Time Partner IBM
Raymond Bergan, M.D., Division Chief of Hematology and Medical Oncology and professor of medicine at OHSU, says that the majority of cancer treatment therapies today are directed toward killing cancer. To date, he says, no one has developed a therapy that can stop cancer cells from moving around the body. quot;For the vast majority of cancer breast, prostate, lung, colon, and others if it is detected early when it is a little lump in that organ and it has not spread, you will live. And generally, if you find it late, after it has spread throughout your body, you will die, quot; says Bergan, also the associate director of medical oncology in the OHSU Knight Cancer Institute and director of the OHSU Bergan Basic Research Laboratory. quot;Movement is key: the difference is black and white, night and day. If cancer cells spread throughout your body, they will take your life. We can treat it, but it will take your life. quot;
Apollo Hospitals will build on its long legacy of clinical excellence with dedicated cancer care hospitals in India by implementing Watson for Oncology and Watson for Genomics across ten of its 64 hospitals. Watson for Oncology will be available at the Apollo Chennai and Delhi hospital from April 2018, followed by Hyderabad, Mumbai, Kolkata, Ahmedabad, Bhubaneshwar and Madurai over the next few months. Watson for Genomics will become available across the same locations in the following months. The Watson for Oncology and Watson for Genomics solutions will help oncologists at Apollo surface relevant data to bridge disparate sources of information and identify treatments that are personalized to each unique patient. Apollo Hospitals has been dedicated to providing patients with best in class cancer care for more than two decades now. Our collaboration with IBM is a reinforcement of our commitment to clinical excellence, said Preetha Reddy, Vice Chairperson of the Apollo Hospitals Group. Each person s cancer journey is unique and hence each patient s treatment plan must be unique too. IBM Watson for Oncology and Genomics will help the clinicians and oncologists at Apollo Hospitals augment their own expertise to deliver an unparalleled and personalized patient care across our hospitals.
There are 50 hospitals on 5 continents that use Watson for Oncology, an IBM product that charges doctors to ingest their cancer patients' records and then make treatment recommendations and suggest journal articles for further reading. READ THE REST These ergonomic earbuds were made to take anywhere Whether you have a long commute or an intense workout to get through, the right music can make the experience much more manageable. Magnetic, long lasting, and enjoyably ergonomic, the N1 Bluetooth Wireless In Ear Headphones make it easy to bring your music with you and tune in with maximum comfort. They;re available in the Boing Boing Store hellip; Life gets busy; and, while some things are bound to fall through the cracks, celebrating your mom on Mother 's Day shouldn 't be one of them. The Bouqs Company and Teleflora are both running specials on Mother 's Day bouquets and can deliver them straight to your mom 's doorstep for a fraction of what you 'd pay at hellip;
It started to hit Dr. David Nanus, chief of hematology and oncology at Weill Cornell Medicine and NewYork Presbyterian. About one in 10 of the patients he sees with a condition like advanced prostate cancer has a mutation in their DNA associated with the cancer that can be useful in treating the disease. So testing that inherited DNA is becoming a more common occurrence.
The team, which was led by the Department of Physics and the Department of Surgery and Cancer at Imperial College London recently described the technology, which is called ”Digistain ”, in the journal Convergent Science Physical Oncology.
;Based on previous research, we studied blueberry extract to verify if it could be used as a radiosensitiser,; Fang added. Radiosensitisers are non toxic chemicals that make cancer cells more responsive to radiation therapy. An earlier study had showed that resveratrol a compound in red grapes could be used as a radiosensitiser for treating prostate cancer. Blueberries also contain resveratrol.For the study, published in the journal Pathology and Oncology Magazine, researchers used human cervical cancer cell lines to mimic clinical treatment. The cell lines were divided into four groups that included a control group, a group that received only radiation, a group that received only blueberry extract and a group that received both radiation and the extract.
Credit: Harini Kantamneni and Professor Prabhas Moghe Rutgers University New Brunswick Using light emitting nanoparticles, Rutgers University New Brunswick scientists have invented a highly effective method to detect tiny tumors and track their spread, potentially leading to earlier cancer detection and more precise treatment.The technology could improve patient cure rates and survival times. We ve always had this dream that we can track the progression of cancer in real time, and that s what we ve done here, said Prabhas V. Moghe, a corresponding author of the study and distinguished professor of biomedical engineering and chemical and biochemical engineering at Rutgers New Brunswick. We ve tracked the disease in its very incipient stages. The study, published online in Nature Biomedical Engineering, shows that the new method is better than magnetic resonance imaging (MRI) and other cancer surveillance technologies. The research team included Rutgers flagship research institution (Rutgers University New Brunswick) and its academic health center (Rutgers Biomedical and Health Sciences, or RBHS). The Achilles heel of surgical management for cancer is the presence of micro metastases. This is also a problem for proper staging or treatment planning. The nanoprobes described in this paper will go a long way to solving these problems, said Dr. Steven K. Libutti, director of Rutgers Cancer Institute of New Jersey. He is senior vice president of oncology services for RWJBarnabas Health and vice chancellor for cancer programs for Rutgers Biomedical and Health Sciences.The ability to spot early tumors that are starting to spread remains a major challenge in cancer diagnosis and treatment, as most imaging methods fail to detect small cancerous lesions. But the Rutgers study shows that tiny tumors in mice can be detected with the injection of nanoprobes, which are microscopic optical devices, that emit short wave infrared light as they travel through the bloodstream even tracking tiny tumors in multiple organs.The nanoprobes were significantly faster than MRIs at detecting the minute spread of tiny lesions and tumors in the adrenal glands and bones in mice. That would likely translate to detection months earlier in people, potentially resulting in saved lives, said Vidya Ganapathy, a corresponding author and assistant research professor in the Department of Biomedical Engineering. Cancer cells can lodge in different niches in the body, and the probe follows the spreading cells wherever they go, she said. You can treat the tumors intelligently because now you know the address of the cancer. The technology could be used to detect and track the 100 plus types of cancer, and could be available within five years, Moghe said. Real time surveillance of lesions in multiple organs should lead to more accurate pre and post therapy monitoring of cancer. You can potentially determine the stage of the cancer and then figure out what s the right approach for a particular patient, he said.In the future, nanoprobes could be used in any surgeries to mark tissues that surgeons want to remove, the researchers said. The probes could also be used to track the effectiveness of immunotherapy, which includes stimulating the immune system to fight cancer cells.This article has been republished from materials provided by Rutgers University. Note: material may have been edited for length and content. For further information, please contact the cited source.Reference:Kantamneni, H., Zevon, M., Donzanti, M. J., Zhao, X., Sheng, Y., Barkund, S. R., . . . Moghe, P. V. (2017). Surveillance nanotechnology for multi organ cancer metastases. Nature Biomedical Engineering, 1(12), 993 1003. doi:10.1038 s41551 017 0167 9
The group s announcement this week puts them with groups in Europe, Australia and elsewhere that have drawn the link through a growing number of studies.Though the added risks are small, they add up among a large population, the group writes in their Journal of Clinical Oncology.
Oops Your browser is ancient :( Upgrade to a different browser or install Google Chrome Frame to experience this site.Although research has demonstrated that all types of alcohol consumption increase cancer risk, most people (including doctors) aren 't aware of this. Now, the American Society of Clinical Oncology has issued a statement to help raise awareness on this issue they want you to know that even drinking in moderation can be dangerous.